STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if the combination is safe and helps the immune system fight cancer more effectively. Ab…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New drug cocktail targets Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
New cocktail targets untreatable liver cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining an immunotherapy drug (nivolumab) with chemotherapy (fluorouracil) and an immune stimulant (interferon alpha 2b) can safely shrink or control fibrolamellar liver cancer that cannot be removed by surgery. The study will enroll 15…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New combo therapy aims to boost immune attack on liver tumors
Disease control Recruiting nowThis phase 2 trial tests whether giving the immune-boosting drugs durvalumab (with or without tremelimumab) after radiation therapy can shrink advanced liver cancer that has spread. About 21 adults whose cancer has progressed on or after prior immunotherapy will receive radiation…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mary Feng, MD • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Could a painkiller boost immunotherapy in liver cancer?
Disease control Recruiting nowThis phase 2 trial tests whether adding celecoxib (a painkiller) to two immunotherapy drugs (durvalumab and tremelimumab) can help control advanced or metastatic liver cancer. About 39 adults with liver cancer that has spread will receive the combination. The goal is to see if it…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New combo therapy for unresectable liver cancer shows promise in early trial
Disease control Recruiting nowThis study tests a new treatment for people with advanced liver cancer that cannot be removed by surgery. The approach combines high-dose radiation, a personalized vaccine made from the patient's own immune cells, and immunotherapy drugs to help the body fight the tumor. The goal…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
New drug AU409 enters first human tests for tough liver cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called AU409 in 36 adults with advanced liver cancer or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers also look for early signs that the drug might shrink or s…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Radiation plus immunotherapy may boost survival in advanced liver cancer
Disease control Recruiting nowThis study is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs alone versus immunotherapy plus targeted radiation (SBRT). The goal is to see if adding radiation helps people live longer. About 226 adults will …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Electric field device joins forces with cancer drugs in early trial
Disease control Recruiting nowThis early-phase study tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The goal is to find …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
Can radiation kickstart the immune system against stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
Liver cancer patients get second chance with new combo therapy
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (atezolizumab) to a standard targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed. Participants must have already re…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
Scientists peek inside tumors during surgery to see how they behave
Knowledge-focused Recruiting nowThis study uses a special microscope to look at blood vessels inside solid tumors while patients are having surgery. The goal is to understand how these vessels work, which could help doctors decide if a patient's tumor is likely to respond to certain treatments. About 85 adults …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC